Literature DB >> 26825660

Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis.

D B Hoffmann1, S Sehmisch2, A M Hofmann2, C Eimer2, M Komrakova2, D Saul2, M Wassmann3, K M Stürmer2, M Tezval2.   

Abstract

We investigated the combinatorial effects of whole-body vertical vibration (WBVV) with the primarily osteoanabolic parathyroid hormone (PTH) and the mainly antiresorptive strontium ranelate (SR) in a rat model of osteoporosis. Ovariectomies were performed on 76 three-month-old Sprague-Dawley rats (OVX, n = 76; NON-OVX, n = 12). After 8 weeks, the ovariectomized rats were divided into 6 groups. One group (OVX + PTH) received daily injections of PTH (40 µg/kg body weight/day) for 6 weeks. Another group (OVX + SR) was fed SR-supplemented chow (600 mg/kg body weight/day). Three groups (OVX + VIB, OVX + PTH + VIB, and OVX + SR + VIB) were treated with WBVV twice a day at 70 Hz for 15 min. Two groups (OVX + PTH + VIB, OVX + SR + VIB) were treated additionally with PTH and SR, respectively. The rats were killed at 14 weeks post-ovariectomy. The lumbar vertebrae and femora were removed for biomechanical and morphological assessment. PTH produced statistically significant improvements in biomechanical and structural properties, including bone mineral density (BMD) and trabecular bone quality. In contrast, SR treatment exerted mild effects, with significant effects in cortical thickness only. SR produced no significant improvement in biomechanical properties. WBVV as a single or an adjunctive therapy produced no significant improvements. In conclusion, vibration therapy administered as a single or dual treatment had no significant impact on bones affected by osteoporosis. PTH considerably improved bone quality in osteoporosis cases and is superior to treatment with SR.

Entities:  

Keywords:  Osteoporosis; PTH; Rat model of osteoporosis; Strontium ranelate; Whole-body vertical vibration

Mesh:

Substances:

Year:  2016        PMID: 26825660     DOI: 10.1007/s00774-016-0736-0

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  44 in total

Review 1.  The Utah paradigm of skeletal physiology: an overview of its insights for bone, cartilage and collagenous tissue organs.

Authors:  H M Frost
Journal:  J Bone Miner Metab       Date:  2000       Impact factor: 2.626

2.  Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical bone.

Authors:  C Rubin; A S Turner; C Mallinckrodt; C Jerome; K McLeod; S Bain
Journal:  Bone       Date:  2002-03       Impact factor: 4.398

3.  PTH (1-34), but not strontium ranelate counteract loss of trabecular thickness and bone strength in disuse osteopenic rats.

Authors:  Annemarie Brüel; Jens Bay Vegger; Anders Christer Raffalt; Jens Enevold Thaulov Andersen; Jesper Skovhus Thomsen
Journal:  Bone       Date:  2012-12-11       Impact factor: 4.398

Review 4.  Strontium ranelate improves bone microarchitecture in osteoporosis.

Authors:  Neveen A T Hamdy
Journal:  Rheumatology (Oxford)       Date:  2009-10       Impact factor: 7.580

5.  Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

Authors:  John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold
Journal:  Toxicol Pathol       Date:  2002 May-Jun       Impact factor: 1.902

6.  Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).

Authors:  A Fahrleitner-Pammer; B L Langdahl; F Marin; F Jakob; D Karras; A Barrett; Ö Ljunggren; J B Walsh; G Rajzbaum; C Barker; W F Lems
Journal:  Osteoporos Int       Date:  2010-11-27       Impact factor: 4.507

7.  Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment.

Authors:  Lucas R Brun; Ana M Galich; Eduardo Vega; Helena Salerni; Laura Maffei; Valeria Premrou; Pablo R Costanzo; Marcelo A Sarli; Paula Rey; María S Larroudé; María S Moggia; María L Brance; Ariel Sánchez
Journal:  Springerplus       Date:  2014-11-18

8.  Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur.

Authors:  M Tezval; E K Stuermer; S Sehmisch; T Rack; A Stary; M Stebener; F Konietschke; K M Stuermer
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

9.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

Review 10.  Pharmacological management of osteogenesis.

Authors:  Valeria Nardone; Federica D'Asta; Maria Luisa Brandi
Journal:  Clinics (Sao Paulo)       Date:  2014-06       Impact factor: 2.365

View more
  3 in total

1.  Effects of RANKL Knockdown by Virus-like Particle-Mediated RNAi in a Rat Model of Osteoporosis.

Authors:  Daniel B Hoffmann; Jens Gruber; Kai O Böker; Delia Deppe; Stephan Sehmisch; Arndt F Schilling; Nicolas Lemus-Diaz; Marina Komrakova; Stefan Schneider
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-11       Impact factor: 8.886

2.  Effect of alendronate or 8-prenylnaringenin applied as a single therapy or in combination with vibration on muscle structure and bone healing in ovariectomized rats.

Authors:  M Komrakova; C Rechholtz; N Pohlmann; W Lehmann; A F Schilling; R Wigger; S Sehmisch; D B Hoffmann
Journal:  Bone Rep       Date:  2019-08-27

3.  Enhanced Bone Formation in Osteoporotic Mice by a Novel Transplant Combined with Adipose-derived Stem Cells and Platelet-rich Fibrin Releasates.

Authors:  Shi-Yuan Sheu; Yuan-Kai Hsu; Ming-Hsi Chuang; Chi-Ming Chu; Po-Cheng Lin; Jeng-Hao Liao; Shinn-Zong Lin; Tzong-Fu Kuo
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.